Efficacy and Safety of Morning Versus Evening Intake of Simvast CR Tablet in Patients With Hyperlipidemia: A Randomized, Double-blind, Multicenter Phase 3 Trial.

Trial Profile

Efficacy and Safety of Morning Versus Evening Intake of Simvast CR Tablet in Patients With Hyperlipidemia: A Randomized, Double-blind, Multicenter Phase 3 Trial.

Completed
Phase of Trial: Phase III

Latest Information Update: 17 Oct 2016

At a glance

  • Drugs Simvastatin (Primary)
  • Indications Hyperlipidaemia
  • Focus Therapeutic Use
  • Sponsors Hanmi Pharmaceutical
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 29 Aug 2013 Results published in the Clinical Therapeutics.
    • 29 Aug 2013 Primary endpoint 'LDL-cholesterol-level' has been met.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top